Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies

BackgroundStudies of the association between the plasma concentration of lipoprotein(a) [Lp(a)] and coronary heart disease (CHD) have reported apparently conflicting findings. We report a meta-analysis of the prospective studies with at least 1 year of follow-up published before 2000. Methods and ResultsThe following information was abstracted for each study: geographical location of study, size, type of cohort (population-based or selected because of previous disease), mean age, follow-up duration, blood storage temperature and duration, assay methods, degree of adjustment for potential confounders, and relationship of baseline Lp(a) measurement with subsequent CHD risk. There were 5436 deaths from CHD or nonfatal myocardial infarctions during a weighted mean follow-up of 10 years in the 27 eligible studies. Comparison of individuals in the top third of baseline plasma Lp(a) measurements with those in the bottom third in each study yielded a combined risk ratio of 1.6 (95% CI 1.4 to 1.8, 2 P <0.00001), with similar findings when the analyses were restricted to the 18 studies of general populations (combined risk ratio 1.7, 95% CI 1.4 to 1.9; 2 P <0.00001). Despite differences among studies in blood storage techniques and assay methods, there was no significant heterogeneity among the results from the 18 population-based studies or among those from the 9 studies of patients with previous disease. Lp(a) was only weakly correlated with classical vascular risk factors, and adjustment for those that had been recorded made little difference to the reported risk ratios. ConclusionsThese prospective studies demonstrate a clear association between Lp(a) and CHD, but further studies are needed to determine the extent to which this is causal.

[1]  M. Koschinsky,et al.  Lipoprotein(a) concentration and apolipoprotein(a) size: A synergistic role in advanced atherosclerosis? , 1999, Circulation.

[2]  F. Kronenberg,et al.  Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. , 1999, Circulation.

[3]  R. Collins,et al.  Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. , 1999, American journal of epidemiology.

[4]  S. Watanabe,et al.  Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. , 1999, Kidney international. Supplement.

[5]  A. Moss,et al.  Thrombogenic factors and recurrent coronary events. , 1999, Circulation.

[6]  P. Fratino,et al.  Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age. , 1999, Journal of the American College of Cardiology.

[7]  M. Koschinsky,et al.  Lipoprotein(a) as a risk factor for coronary artery disease. , 1998, The American journal of cardiology.

[8]  J. Shepherd Preventing coronary artery disease in the West of Scotland: implications for primary prevention. , 1998, The American journal of cardiology.

[9]  Stenlund,et al.  Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein A‐I is protective for the incidence of primary acute myocardial infarction in middle‐aged males. An incident case–control study from Sweden , 1998, Journal of internal medicine.

[10]  J. Haddow,et al.  Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. , 1998, Clinical chemistry.

[11]  D. Lane,et al.  Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. , 1998, European heart journal.

[12]  R Peto,et al.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.

[13]  L. Wilhelmsen,et al.  Serum lipids, lipoprotein(a) and apo(a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery. , 1998, Atherosclerosis.

[14]  G. Dagenais,et al.  Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. , 1998, Journal of the American College of Cardiology.

[15]  E. Wall,et al.  Gated SPECT radionuclide angiography: what is the gain? , 1998 .

[16]  J. Kjekshus,et al.  Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study , 1997, Clinical genetics.

[17]  K. Bailey,et al.  Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. , 1997, Circulation.

[18]  M. Farrer,et al.  Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery. , 1997, Heart.

[19]  M. Schroll,et al.  Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study. , 1997, Atherosclerosis.

[20]  D. Nagel,et al.  Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. , 1997, Atherosclerosis.

[21]  S. Fortmann,et al.  A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[22]  F. Kronenberg,et al.  Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[23]  P. Wilson,et al.  Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. , 1996, JAMA.

[24]  A. von Eckardstein,et al.  Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. , 1996, The American journal of cardiology.

[25]  B. G. Brown,et al.  Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). , 1995, JAMA.

[26]  P. Wilson,et al.  A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. , 1994, Circulation.

[27]  M. Mittleman,et al.  Lipoprotein(a) in coronary heart disease. Is it a risk factor after all? , 1994, JAMA.

[28]  J. Ordovás,et al.  Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. , 1994, JAMA.

[29]  J. Salonen,et al.  Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. , 1994, Atherosclerosis.

[30]  N. Wald,et al.  Apolipoproteins and ischaemic heart disease: implications for screening , 1994, The Lancet.

[31]  E. Barnathan Has lipoprotein 'little' (a) shrunk? , 1993, JAMA.

[32]  P. Ridker,et al.  A prospective study of lipoprotein(a) and the risk of myocardial infarction. , 1993, JAMA.

[33]  R. Heyka,et al.  Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Hemodialysis Patients , 1992, Circulation.

[34]  G. Thorgeirsson,et al.  Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. , 1992, The American journal of cardiology.

[35]  R. Klein,et al.  Lack of association between lipoprotein (a) concentrations and coronary heart disease mortality in diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. , 1992, Metabolism: clinical and experimental.

[36]  M. Pike,et al.  A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. , 1992, Atherosclerosis.

[37]  J. Huttunen,et al.  Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. , 1991, Atherosclerosis.

[38]  L. Wilhelmsen,et al.  Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. , 1990, BMJ.

[39]  G. Dahlén Lipoprotein (a) as a risk factor for atherosclerotic diseases. , 1988, Arctic medical research.

[40]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.